On-demand Webinar: From Data to Decisions in Antibody Discovery – Integrating AI/ML
Download our webinar on Data to Decisions in Antibody Discovery – Integrating AI/ML. Watch now Webinar Overview: In this webinar, Alloy will share practical, production-grade AI/ML workflows for candidate selection, developability triage, and optimization. We’ll cover what works today, what doesn’t, and how integrated data infrastructure and high-throughput make-test loops turn models into compounding advantage. […]
Poster | Transient-Cyclic Structured Oligonucleotides
Explore the science behind AntiClastic™ cyclic oligonucleotide design. Download the poster Contact Us Poster Overview: This poster highlights a novel approach to antisense architecture using transient cyclic structures designed to improve potency, reduce immune activation, and enhance the overall drug-like properties of RNA therapeutics. Download the poster to see how cyclic design can help overcome […]
Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform
BOSTON — March 17, 2026 — Alloy Therapeutics, Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced an agreement with AbbVie to develop a new antibody platform to discover potent, specific, and effective antibodies against targets that are difficult to address with current technologies. As part of […]
AI/ML in Antibody Discovery: What Works, What Doesn’t, What’s Next
Traditional antibody discovery is a war of attrition: screen thousands of candidates, fail late, and repeat. AI/ML changes that calculus by shifting failures from late and expensive to early and cheap. The result is fewer wet-lab cycles and a higher probability that the molecules you carry forward actually behave like drugs, while at the same time integrating learnings from failures at every stage.
From Data to Decisions in Antibody Discovery: Integrating AI/ML
WEBINAR Register for our upcoming webinar on integrating AI/ML workflows to drive smarter antibody selection, developability triage, and lead optimization. Tue, Mar. 31 | 11:00 AM EST Register Now Webinar Overview: AI/ML is reshaping antibody discovery, not by replacing the lab, but by making every wet-lab cycle smarter. In this webinar, Alloy will share practical, […]
Alloy Accelerates Mediar Timeline to the Clinic for Complex Fibrosis Targets
Antibody discovery for complex fibrosis targets requires advanced platforms capable of addressing difficult biology. Alloy Therapeutics partnered with Mediar to accelerate high-quality antibody programs into IND-enabling studies.
Accelerated Antibody Discovery for Complex Fibrosis Targets
Accelerating Antibody Discovery for Challenging Fibrosis Targets Download Case Study Contact Us Advancing a first-in-class fibrosis program against complex biology This case study highlights how Alloy’s antibody discovery platforms and execution model enabled Mediar Therapeutics to move a complex fibrosis program forward with speed and confidence, despite biological and technical barriers that stalled conventional discovery […]
Tahoe Therapeutics and Alloy Therapeutics to Form Joint Venture and Develop First-in-Class Antibody-Drug Conjugates for Hard-to-Treat Cancers
The new company combines Tahoe’s AI-powered target discovery engine with Alloy’s industry-leading ADC development capabilities to advance two first-in-class oncology programs built on deeply validated tumor targets.
Swiss Rockets Group and Alloy Therapeutics Partner to Advance Radioligand Therapeutics in Oncology
Collaboration combines Alloy’s antibody discovery and engineering platforms with Torpedo’s radiopharmaceutical development capabilities – including Terbium-161 – to advance next-generation oncology RLT candidates toward clinical development
Leveraging Human Lambda Light Chains in Antibody Discovery
Harnessing the potential of human lambda light chains in antibody discovery Download White Paper Contact Us Expanding antibody discovery potential with human lambda light chains Despite the kappa/lambda ratio in human circulation being between 1.5 and 2, therapeutic antibodies remain heavily biased toward kappa light chain usage. Our white paper explores how Alloy’s ATX-GL platform […]